Get the Stockscreener App
50.26
1.68%
-0.86
Cytokinetics Inc stock is traded at $50.26, with a volume of 2.14M.
It is down -1.68% in the last 24 hours and up +9.69% over the past month.
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$51.12
Open:
$51.57
24h Volume:
2.14M
Relative Volume:
1.56
Market Cap:
$5.93B
Revenue:
$3.22M
Net Income/Loss:
$-576.40M
P/E Ratio:
-9.342
EPS:
-5.38
Net Cash Flow:
$-407.05M
1W Performance:
+8.88%
1M Performance:
+9.69%
6M Performance:
-11.17%
1Y Performance:
-34.30%
1-Day Range:
$48.88
$51.74
1-Week Range:
$45.05
$51.74
52-Week Range:
$40.53
$81.36
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
50.26 | 5.93B | 3.22M | -576.40M | -407.05M | -5.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Cytokinetics (CYTK) Projected to Post Earnings on Tuesday - MarketBeat
Allspring Global Investments Holdings LLC Has $4.11 Million Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Van ECK Associates Corp - MarketBeat
Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - MSN
Insider Sell: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Fady Ibraham Malik Sells 2,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Inside Cytokinetics' Latest Employee Compensation Strategy: $46.16 Stock Options and RSU Details Revealed - StockTitan
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Peregrine Capital Management LLC - MarketBeat
Cytokinetics EVP sells $91,960 in stock By Investing.com - Investing.com South Africa
Stifel maintains Buy on Cytokinetics stock, target at $80 By Investing.com - Investing.com Canada
Cytokinetics EVP sells $91,960 in stock - Investing.com
Cytokinetics (NASDAQ:CYTK) Stock Price Up 7.6%Time to Buy? - MarketBeat
Cytokinetics stock touches 52-week low at $41.69 amid market challenges - MSN
Cytokinetics (NASDAQ:CYTK) Upgraded by Morgan Stanley to "Overweight" Rating - MarketBeat
Cytokinetics jumps amid renewed takeover speculation - MSN
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study - MSN
Cytokinetics (NASDAQ:CYTK) Reaches New 1-Year LowHere's What Happened - MarketBeat
Harvey Capital Management Inc. Acquires Shares of 22,105 Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics upgraded by Morgan Stanley on upside potential - MSN
Morgan Stanley Upgrades Cytokinetics (CYTK) - MSN
Cytokinetics to Announce Fourth Quarter Results on February 27, 2025 - EIN News
Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70 - Marketscreener.com
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Morgan Stanley lifts Cytokinetics stock rating, cuts target to $67 - MSN
Morgan Stanley lifts Cytokinetics stock rating, cuts target to $67 By Investing.com - Investing.com UK
Cytokinetics adds pharma veteran Landry to board ahead of drug launch - Investing.com Nigeria
Cytokinetics' (CYTK) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Citigroup - MarketBeat
Cytokinetics Names Robert E. Landry to Board of Directors - GlobeNewswire
Cytokinetics adds pharma veteran Landry to board ahead of drug launch By Investing.com - Investing.com South Africa
Cytokinetics Appoints Robert E. Landry to Board - TipRanks
Cytokinetics Names Robert E. Landry To Board Of Directors -February 11, 2025 at 07:53 am EST - Marketscreener.com
Cytokinetics Appoints Robert E. Landry to Board of Directors to Enhance Financial and Operational Expertise as Company Prepares for Commercialization - Nasdaq
abrdn plc Acquires 102,457 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Sets New 12-Month LowShould You Sell? - MarketBeat
JMP Securities maintains Cytokinetics stock with $78 target - MSN
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Feb 18 '25 |
Sale |
45.98 |
2,000 |
91,960 |
116,071 |
| Malik Fady Ibraham | EVP Research & Development |
Feb 04 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
118,071 |
| Malik Fady Ibraham | EVP Research & Development |
Feb 04 '25 |
Sale |
48.06 |
2,000 |
96,120 |
116,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 21 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
118,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 21 '25 |
Sale |
45.92 |
2,000 |
91,840 |
116,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 07 '25 |
Option Exercise |
10.60 |
2,000 |
21,200 |
118,071 |
| Malik Fady Ibraham | EVP Research & Development |
Jan 07 '25 |
Sale |
49.32 |
2,000 |
98,640 |
116,071 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):